A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
Top Cited Papers
- 1 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (13), 3126-3134
- https://doi.org/10.1158/1078-0432.CCR-19-4042
Abstract
Purpose: We hypothesized that autophagy inhibition would increase response to chemotherapy in the preoperative setting for patients with pancreatic adenocarcinoma. We performed a randomized controlled trial to assess the autophagy inhibitor hydroxychloroquine in combination with gemcitabine and nab-paclitaxel. Patients and Methods: Participants with potentially resectable tumors were randomized to two cycles of nab-paclitaxel and gemcitabine (PG) alone or with hydroxychloroquine (PGH), followed by resection. The primary endpoint was histopathologic response in the resected specimen. Secondary dinical endpoints included serum CA 19-9 biomarker response and margin negative RO resection. Exploratory endpoints included markers of autophagy, immune infiltrate, and serum cytokines. Results: Thirty-four patients in the PGH arm and 30 in the PG arm were evaluable for the primary endpoint. The PGH arm demonstrated statistically improved Evans grade histopathologic responses (P = 0.00016), compared with control. In patients with elevated CA 19-9, a return to normal was associated with improved overall and recurrence-free survival (P < 0.0001). There were no differences in serious adverse events between arms and chemotherapy dose number was equivalent. The PGH arm had greater evidence of autophagy inhibition in their resected specimens (increased SQSTMI, P = 0.027, as well as increased immune cell tumor infiltration, P = 0.033). Overall survival (P = 0.59) and relapse-free survival (P = 055) did not differ between the two arms. Conclusions: The addition of hydroxychloroquine to preoperative gerncitabine and nab-paclitaxel chemotherapy in patients with resectable pancreatic adenocarcinoma resulted in greater pathologic tumor response, improved serum biomarker response, and evidence of autophagy inhibition and immune activity.Other Versions
Funding Information
- NIH (1R01 CA181450)
- NIH (R01GM115366)
- NIH (R01CA206012)
This publication has 34 references indexed in Scilit:
- Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasisGenes & Development, 2013
- Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment StrategiesCell, 2012
- Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinomaCancer, 2011
- Pancreatic cancers require autophagy for tumor growthGenes & Development, 2011
- Principles and Current Strategies for Targeting Autophagy for Cancer TreatmentClinical Cancer Research, 2011
- The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiationInternational Journal of Oncology, 2010
- Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinomaHPB, 2009
- Practical Bayesian adaptive randomisation in clinical trialsEuropean Journal of Cancer, 2007
- Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival DurationAnnals of Surgical Oncology, 2001
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992